Workflow
FILSPARI® (sparsentan)
icon
搜索文档
Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026
Businesswire· 2026-10-02 22:00
SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that it will share nine new data presentations, including five oral presentations, at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, CO, October 21-25. The presentations highlight compelling new data on FILSPARI® (sparsentan) in patients with IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS)."The final SPARTAN analysis provides a compelling picture of what's possible whe. ...